CAMBRIDGE, Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025.
Leap Highlights:
"This past quarter, we undertook a strategic realignment to focus our resources on corporate development opportunities for sirexatamab and FL-501," said Douglas E. Onsi, President and CEO of Leap Therapeutics. "As part of this effort, we completed patient treatment in the DeFianCe trial, further reduced internal expenses, and initiated a review of strategic alternatives to maximize value for our shareholders. We intend to provide a further update in the coming weeks. We are grateful to all of our team members, and we thank them for their important contributions to Leap and their commitment to developing new therapies for cancer patients."
DKN-01 Development Update
Business Updates
Selected Second Quarter 2025 Financial Results
Net Loss was $16.6 million for the second quarter 2025, compared to $20.4 million for the second quarter 2024. The decrease was primarily due to a decrease in research and development and general and administrative expenses, offset in part by a restructuring charge associated with the reduction in force.
Research and development expenses were $10.5 million for the second quarter of 2025, compared to $17.9 million for the same period in 2024. The decrease of $7.4 million was primarily due to decreases of $3.9 million in clinical trial costs, $1.7 million in payroll and other headcount related expenses, $1.4 million in manufacturing costs, and $0.4 million in stock-based compensation expense.
General and administrative expenses were $1.8 million for the second quarter 2025, compared to $3.4 million for the same period in 2024. The decrease of $1.6 million was primarily due to decreases of $1.4 million in payroll and other incentive based compensation expense and a $0.2 million decrease in stock-based compensation expense.
During the second quarter of 2025, we incurred $4.5 million of restructuring charges associated with our workforce reduction, consisting primarily of one-time employee severance and benefit costs.
Cash and cash equivalents totaled $18.1 million on June 30, 2025.
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's pipeline includes sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, and FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the federal securities laws. Such statements are based upon current plans, estimates and expectations of the management of Leap that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "anticipate," "expect," "project," "intend," "believe," "may," "will," "should," "plan," "could," "continue," "target," "contemplate," "estimate," "forecast," "guidance," "predict," "possible," "potential," "pursue," "likely," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements.
All statements, other than historical facts, including statements regarding the potential safety, efficacy, and regulatory and clinical progress of Leap's product candidates, including sirexatamab and FL-501; Leap's plan to reduce clinical and operational activities, reduce spending and conserve cash, explore strategic alternatives to preserve and maximize shareholder value, including by leveraging its cash balance and potentially selling or partnering sirexatamab or FL-501; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Leap's plans, estimates or expectations could include, but are not limited to: (i) Leap's ability to successfully sell or enter into partnerships for sirexatamab or FL-501; (ii) the cost and timeline to complete the DeFianCe Study and wind-down operations; (iii) any regulatory feedback that Leap may receive from U.S. Food and Drug Administration (FDA) or equivalent foreign regulatory agency or from site institutional review boards; and (iv) the availability of strategic alternatives that would preserve or generate any shareholder value. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Leap may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Leap's most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither Leap, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Leap's views as of any date subsequent to the date hereof.
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
This email address is being protected from spambots. You need JavaScript enabled to view it.
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
This email address is being protected from spambots. You need JavaScript enabled to view it.
Leap Therapeutics, Inc. | ||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||
(In thousands, except share and per share amounts) | ||||||||||||
(Unaudited) | ||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
Operating expenses: | ||||||||||||
Research and development | $ | 10,537 | $ | 17,885 | $ | 23,448 | $ | 29,184 | ||||
General and administrative | 1,817 | 3,367 | 4,823 | 6,893 | ||||||||
Restructuring charges | 4,527 | — | 4,527 | — | ||||||||
Total operating expenses | 16,881 | 21,252 | 32,798 | 36,077 | ||||||||
Loss from operations | (16,881) | (21,252) | (32,798) | (36,077) | ||||||||
Interest income | 246 | 865 | 683 | 1,640 | ||||||||
Interest expense | (7) | — | (13) | — | ||||||||
Australian research and development incentives | 1 | 253 | 56 | 499 | ||||||||
Foreign currency gain (loss) | (2) | 6 | (6) | (10) | ||||||||
Net loss | $ | (16,643) | $ | (20,128) | $ | (32,078) | $ | (33,948) | ||||
Dividend attributable to down round feature of warrants | — | (234) | — | (234) | ||||||||
Net loss attributable to common stockholders | $ | (16,643) | $ | (20,362) | $ | (32,078) | $ | (34,182) | ||||
Net loss per share | ||||||||||||
Basic and diluted | $ | (0.40) | $ | (0.52) | $ | (0.78) | $ | (1.01) | ||||
Weighted average common shares outstanding | ||||||||||||
Basic and diluted | 41,444,979 | 39,122,662 | 41,357,423 | 33,830,083 | ||||||||
Leap Therapeutics, Inc. | ||||||
Condensed Consolidated Balance Sheets | ||||||
(In thousands, except share and per share amounts) | ||||||
June 30, | December 31, | |||||
2025 | 2024 | |||||
Assets | ||||||
Current assets: | ||||||
Cash and cash equivalents | $ | 18,130 | $ | 47,249 | ||
Research and development incentive receivable | 739 | 704 | ||||
Prepaid expenses and other current assets | 292 | 86 | ||||
Total current assets | 19,161 | 48,039 | ||||
Right of use assets, net | 38 | 262 | ||||
Research and development incentive receivable, net of current portion | 59 | — | ||||
Deposits | 784 | 823 | ||||
Total assets | $ | 20,042 | $ | 49,124 | ||
Liabilities and Stockholders' Equity | ||||||
Current liabilities: | ||||||
Accounts payable | $ | 7,339 | $ | 4,743 | ||
Accrued expenses | 6,623 | 8,536 | ||||
Income tax payable | 324 | 531 | ||||
Lease liability - current portion | 39 | 266 | ||||
Total current liabilities | 14,325 | 14,076 | ||||
Stockholders' equity: | ||||||
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and | — | — | ||||
Common stock, $0.001 par value; 240,000,000 shares authorized; 41,439,529 and 38,329,894 | 41 | 38 | ||||
Additional paid-in capital | 505,207 | 502,501 | ||||
Accumulated other comprehensive loss | (82) | (120) | ||||
Accumulated deficit | (499,449) | (467,371) | ||||
Total stockholders' equity | 5,717 | 35,048 | ||||
Total liabilities and stockholders' equity | $ | 20,042 | $ | 49,124 | ||
Leap Therapeutics, Inc. | ||||||||||||||
Condensed Consolidated Statements of Cash Flows | ||||||||||||||
(in thousands) | ||||||||||||||
(Unaudited) | (Unaudited) | |||||||||||||
Three Months Ended June 30 | Six Months Ended June 30 | |||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||
Cash used in operating activities | $ (14,486) | $ (13,671) | $ (28,966) | $ (29,187) | ||||||||||
Cash provided by (used in) financing activities | (119) | 37,117 | (180) | 37,146 | ||||||||||
Effect of exchange rate changes on cash and cash equivalents | 22 | 112 | 27 | (123) | ||||||||||
Net increase (decrease) in cash and cash equivalents | (14,583) | 23,558 | (29,119) | 7,836 | ||||||||||
Cash and cash equivalents at beginning of period | 32,713 | 54,921 | 47,249 | 70,643 | ||||||||||
Cash and cash equivalents at end of period | $ 18,130 | $ 78,479 | $ 18,130 | $ 78,479 | ||||||||||
| Last Trade: | US$0.27 |
| Daily Change: | 0.02 10.02 |
| Daily Volume: | 23,740,478 |
| Market Cap: | US$11.110M |
April 25, 2025 March 26, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
